Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95125 trials found · Page 154 of 4757
-
Could a diabetes drug curb alcohol cravings and save livers?
Disease control Recruiting nowBackground: People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal. An approved weight management drug (Tirzepatide) ma…
Phase: PHASE2 • Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA) • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Can a single drug calm inflamed arteries in people with a common gene change?
Disease control Recruiting nowThe primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New device zaps lung arteries to ease heart failure
Disease control Not yet recruitingThe goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associ…
Phase: NA • Sponsor: Pulnovo Medical, Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Can a drug stop lung spots from becoming cancer? new trial for smokers.
Prevention Recruiting nowThe main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Phase: PHASE2 • Sponsor: Robert Samstein • Aim: Prevention
Last updated May 07, 2026 18:42 UTC
-
Could an old drug give new hope for rare bone cancers?
Disease control Not yet recruitingEwing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional thera…
Phase: PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Off-the-Shelf cell therapy takes on tough leukemia in early trial
Disease control Recruiting nowThis study is a single arm, open label, dose exploring clinical trial to evaluate the safety, efficacy, cellular metabolic dynamics, and pharmacodynamics of ct1190b cells in relapsed / refractory B-cell acute lymphoblastic leukemia.
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Magic mushroom therapy targets Cancer's hidden toll: despair
Symptom relief Recruiting nowDemoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness. The relevance of demoralization syndrome in oncology is tied to this syndrom…
Phase: PHASE1 • Sponsor: Gustavo Vazquez • Aim: Symptom relief
Last updated May 15, 2026 11:54 UTC
-
Promising drug may tame rare blood vessel disease and cut steroid use
Disease control Not yet recruitingTakayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular compli…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Resilience training aims to shield first responders from PTSD
Prevention Not yet recruitingAs a result of chronic exposures to traumatic and stressful events, first responders are at elevated risk for experiencing post-traumatic stress disorder (PTSD) and other mental health problems. Resilience training can reduce the risk for developing mental health symptoms in firs…
Phase: NA • Sponsor: Stony Brook University • Aim: Prevention
Last updated May 04, 2026 16:20 UTC
-
New combo therapy aims to turn inoperable liver cancer into operable
Disease control Not yet recruitingThis study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the…
Phase: NA • Sponsor: Hong Wu • Aim: Disease control
Last updated May 16, 2026 11:05 UTC
-
Herbal hope: could ancient remedy slash liver cancer risk in hepatitis b patients?
Disease control Not yet recruitingThis study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort. The cohort will include high-risk populations for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) from multiple centers nationw…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New shot may stop dangerous leaks after pancreas surgery
Prevention Not yet recruitingThis study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of octreotide microspheres in preventing pancreatic fistula after distal pancreatectomy.
Phase: PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Prevention
Last updated May 15, 2026 11:53 UTC
-
New hope for lymphoma patients: drug may keep cancer in check
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction thera…
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 16, 2026 11:04 UTC
-
New hope for elderly blood cancer patients: tailored transplant approach shows promise
Disease control Recruiting nowAcute myeloid leukemia (AML) is one of the most common hematologic malignancies. With increasing life expectancy and the aging of society, the incidence of AML in the elderly population is rising. The prognosis of elderly AML patients is significantly worse than that of younger p…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 16, 2026 11:06 UTC
-
Ready-Made immune cells take on lymphoma and leukemia in first human trial
Disease control Not yet recruitingPhase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated May 04, 2026 16:29 UTC
-
Promising new combo aims to control rare melanoma before and after surgery
Disease control Not yet recruitingThis study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 16, 2026 11:07 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial launches
Disease control Not yet recruitingThis is a Phase II Study of HLX43 in Hormone Receptor Positive,HER-2 negative Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intol…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New keyhole breast surgery could offer better looks and faster recovery
Symptom relief Not yet recruitingThis study is a multicenter, open-label, randomized controlled trial. The study aims to evaluate differences in operative efficiency (e.g., operative time), economic effect, surgical safety (e.g., surgical complication rates), postoperative aesthetics (e.g., BREAST-Q scores, Harr…
Phase: NA • Sponsor: Du Zhenggui • Aim: Symptom relief
Last updated May 01, 2026 16:00 UTC
-
New hope for tough pancreatic cancer: experimental drug targets tumors
Disease control Not yet recruitingThis is a multicenter, prospective, open-label Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab govitecan monotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma who have failed at least one prior line of the…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 16, 2026 11:05 UTC
-
New drug cocktail shows promise for Tough-to-Treat leukemia
Disease control ENROLLING_BY_INVITATIONThis study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment of MPAL.
Phase: PHASE2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC